Preclinical Trial Equipment Supplied In Australasia

FluidCrysta nanoparticles can resolve bioavailability issues for water and lipid-soluble pharmaceuticals or biodegradation-sensitive drugs, such as peptides and proteins. FluidCrystal nanoparticles are usually water-based and comprise a stable emulsion of nanoparticles with a liquid crystalline structure. Investigational medicinal products based on this technology are administered either ...

MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial ...

Advanced colorectal cancer currently has a poor prognosis and is the deadliest form of cancer for Australians 25 to 34 years old. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and other cancers. In colon cancer patients, LGR5+ expression has been correlated with a particularly poor ...

CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...

DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...

DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, ...

Cxcolorectal is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer. The test predicts the aggressiveness of the tumour, allowing physicians to make the best decision regarding treatment for the ...

DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...

BDM-I: Addressing market need for next-generation antimicrobials. Infectious diseases often dominate the media headlines, including rising antibiotic resistance and fear of “super bugs”. One serious problem facing the global community is that anti-infective treatments that were once effective now cannot be relied upon. There are some strains of infections including tuberculosis, blood ...

AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today. Under the Collaboration ...

Designed for the emerging market of preclinical and molecular MR imaging: The BioSpec series is designed for the emerging market of preclinical and molecular MR imaging. State-of-the-art MRI CryoProbe technology together with ultra high field USR magnets deliver high spatial resolution in vivo enabling customers to come closer to the molecular and cellular level ...

MPC-25-Osteo for spinal fusion is a proprietary Phase 3-ready product candidate. All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million MPCs delivered on a collagen ceramic carrier material into the disc space with stabilizing ...

The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform Consists of the Therapeutic Screening Platform, Microbial Optimization Platform, and Microbiome Database ...

AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to the drug target, CXCR4 and demonstrates anti-fibrotic effects in several models of fibrosis. This was initially called AD-114. Following further development, AdAlta ...

MPC-06-ID is a Phase 3 product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections and have no further treatment option other than invasive and costly surgical ...

Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...